Dicerna: Roche Phase 2 Hepatitis B Trial Triggers $25 Million Milestone
By Michael Dabaie
Dicerna Pharmaceuticals Inc. said Roche initiated RG6346 in a
Phase 2 combination trial for the treatment of chronic hepatitis B
virus infection, triggering a $25 million milestone to Dicerna.
RG6346 is an investigational therapeutic that Dicerna is
developing in collaboration with Roche as part of the companies'
collaboration and licensing agreement for chronic HBV
The Phase 2 platform trial will evaluate the efficacy and safety
of RG6346 in combination with multiple additional agents with
different mechanisms of action.
"We are very encouraged by the results from the Phase 1 trial of
RG6346, which have shown a strong and sustained reduction in the
levels of hepatitis B surface antigen," said John Young, global
head of infectious diseases at Roche Pharmaceutical Research and
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
March 04, 2021 09:15 ET (14:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.